NASDAQ$VIR
Vir Biotechnology Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2024.
Vir Biotechnology reported a net loss of $65.3 million, or $(0.48) per share, for the first quarter of 2024. The company's cash, cash equivalents, and investments totaled $1.51 billion as of March 31, 2024. Total revenues for the quarter were $56.4 million, compared to $63.0 million for the same period in 2023.
- Phase 2 chronic hepatitis delta SOLSTICE trial data abstract accepted for poster presentation at EASL Congress 2024.
- Two additional hepatitis program data readouts are on track for the fourth quarter of 2024.
- Cash, cash equivalents, and investments totaled $1.51 billion as of March 31, 2024.
- Virtual R&D day planned for late November.
Headline financials
Revenue & EPS history
Vir · Revenue · Quarterly
$56.4M
Revenue by segment
Vir · $2.35M total across 2 segments · Q3 2023
- Grant revenue$6.74M+117.3%286.7%
- License & collaboration revenue-$4.39M-101.4%-186.7%
Forward guidance
The Company reiterates its full year 2024 guidance below, originally provided on February 22, 2024 (in millions): GAAP combined R&D and SG&A expense range:$650 to$680
Tailwinds
- GAAP combined R&D and SG&A expense range: $650 to $680 million
- Stock-based compensation expense included in the GAAP combined R&D and SG&A expense range.
- Restructuring charges included in the GAAP combined R&D and SG&A expense range.
- Approximately three to four percent of the GAAP combined R&D and SG&A expense will be funded by grants.
- These grants are recognized as revenue.
Headwinds
- The GAAP combined R&D and SG&A expense guidance does not include the effect of GAAP adjustments caused by events that may occur subsequent to the publication of this guidance
- Business development activities are not included.
- Litigation is not included.
- In-process R&D impairments are not included.
- Changes in the fair value of contingent considerations are not included.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+2.0%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
43%
12 / 28 earnings
Positive
+27.7%
Q4 2025
Best reaction
-15.1%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.8% | -7.2% | -13.7% | |
| Q4 2025 | +27.7% | +22.3% | +20.6% | |
| Q3 2025 | -5.6% | -8.9% | +8.3% | |
| Q1 2025 | -3.4% | -16.2% | -2.9% | |
| Q4 2024 | -11.8% | -10.9% | -27.2% | |
| Q3 2024 | +21.8% | +26.8% | +4.7% | |
| Q2 2024 | -9.4% | -15.4% | -18.7% | |
| Q1 2024 | +18.9% | +13.6% | +17.5% | |
| Q4 2023 | +14.0% | +13.1% | -0.6% | |
| Q3 2023 | +12.5% | +8.3% | +24.4% | |
| Q2 2023 | -3.0% | -4.8% | -10.9% | |
| Q1 2023 | -3.5% | -4.5% | +7.5% | |
| Q4 2022 | -14.8% | -15.6% | -16.7% | |
| Q3 2022 | +15.0% | +20.3% | +23.7% | |
| Q2 2022 | +2.0% | -4.9% | -25.9% | |
| Q1 2022 | -3.1% | -1.4% | +12.5% | |
| Q4 2021 | +0.1% | -13.7% | -21.5% | |
| Q3 2021 | -15.1% | -11.7% | +20.4% | |
| Q2 2021 | +3.3% | +10.5% | +32.0% | |
| Q1 2021 | -1.0% | -8.5% | +3.5% | |
| Q4 2020 | -4.2% | -11.7% | -21.2% | |
| Q3 2020 | +8.2% | +5.8% | +26.0% | |
| Q2 2020 | -0.6% | -0.9% | -46.8% | |
| Q2 2019 | -0.6% | -0.9% | -46.8% | |
| Q1 2020 | -1.9% | -3.1% | +7.2% | |
| Q1 2019 | -1.9% | -3.1% | +7.2% | |
| Q4 2019 | +11.5% | +11.4% | +6.0% | |
| Q3 2019 | -3.0% | -0.5% | -3.7% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro